The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 9:19 AM
Here's a roundup of top developments in the biotech space over the last 24 hours.
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure And Improves Outcomes As Oral On-Demand Treatment Of HAE
November 8, 7:38 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data presented at
September 15, 2:57 PM
KalVista Pharmaceuticals (NASDAQ:KALV) shares are trading lower after the FDA notified the company that it has placed a clinical hold on its Phase 2 clinical trial of KVD824.
September 14, 8:20 AM
The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc’s (NASDAQ:KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of…
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
September 9, 8:17 AM
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
September 9, 6:34 AM
KalVista Pharmaceuticals (NASDAQ:KALV) reported quarterly losses of $(0.66) per share. This is a 8.2 percent decrease over losses of $(0.61) per share from the same period last year.